XPG G3507 C多态性与Ⅲ期大肠癌对奥沙利铂化疗敏感性的研究

摘要

目的：探讨Ⅲ期大肠癌患者外周血中XPG G3507C单核苷酸多态性与其对奥沙利铂化疗的临床疗效关系。方法：106例Ⅲ期大肠癌患者化疗前抽取静脉血并提取DNA，以TaqMan探针法对XPG G3507C位点进行SNP分型。患者接受奥沙利铂为基础的化疗方案治疗，比较不同基因型与临床特点及化疗疗效的关系。结果：106例患者的XPG G3507C位点G/G、G/C、C/C基因型分布频率分别为36．8％、47．2％和16．0％。针对性别、年龄、肿瘤部位、初诊时血清癌胚抗原水平、ECOG评分、肿瘤分化程度等因素的分层分析结果显示， XPG G3507C基因型分布无显著差异（P＞0．05）。三种基因型患者的肿瘤复发或转移率、肿瘤相关死亡率、无疾病生存时间和总生存时间均无统计学差异（P＞0．05）。结论：Ⅲ期大肠癌患者外周血中的XPG G3507C单核苷酸多态性与患者临床特征及接受奥沙利铂化疗后的临床疗效可能无相关性。%Objective:To observe the relationship between XPG G3507C gene polymorphism and clinical outcome of patients with stage Ⅲcolorectal cancer treated by oxaliplatin chemotherapy.Methods:DNA was extracted from pe-ripheral venous blood before chemotherapy for 106 stage Ⅲ colorectal cancer patients.XPG G3507C genotypes were determined by TaqMan.All patients were treated with oxaliplatin based chemotherapy regimens.Results:The frequen-cy of G/G,G/C and C/C genotypes was 36.8%,47.2% and 16.0%,respectively(P>0.05).There was no signifi-cant difference between XPG G3507C genotypes and patients'gender,age,tumor location,serum carcinoembryonic an-tigen level,ECOG score and tumor differentiation.No significant difference between genotypes and disease recurrence and metastasis rates,mortality,disease-free survival time and overall survival time was found(P>0.05 ).Conclu-sion:There was no association between XPG G3507C gene polymorphism and clinical characteristic and clinical out-come of patients with stage Ⅲ colorectal cancer treated by oxaliplatin chemotherapy.